AEON AEON Biopharma, Inc.
Price Chart
Executive Summary
AEON Biopharma reported Q1 2026 results with a net loss of $11.8M ($-0.29/share), compared to net income of $9.1M ($2.28/share) in Q1 2025, driven by increased operating expenses and fair-value changes on convertible notes. The company highlighted positive FDA Type 2a feedback for its ABP-450 biosimilar program and a strengthened balance sheet from a $6M PIPE and Daewoong note exchange that reduced debt by over 90%. Cash of $6.2M (plus $0.9M from ATM in April) funds operations into Q3 2026, but the pre-revenue clinical-stage biotech faces a binary regulatory catalyst with no near-term revenue.
Actionable Insight
The FDA Type 2a feedback is a modest positive for the ABP-450 program, but with only ~$7M cash runway into Q3 2026, AEON will likely need additional financing before the Type 2b meeting. The massive share dilution (shares more than doubled) and pre-revenue status limit upside. Watch for the Type 2b meeting in H2 2026 as the next major catalyst.
Key Facts
- Net loss of $11.8M in Q1 2026 vs net income of $9.1M in Q1 2025, driven by operating expense growth and non-cash fair-value adjustments
- Cash and cash equivalents of $6.2M as of March 31, 2026, plus $0.9M from April ATM, funding operations into Q3 2026
- Convertible notes reduced from $34.6M to $1.5M following Daewoong note exchange, cutting outstanding debt by >90%
- FDA BPD Type 2a meeting provided positive feedback on ABP-450 analytical similarity strategy under 351(k) biosimilar pathway
- Shares outstanding more than doubled to 25.3M from 12.1M at year-end 2025, reflecting PIPE and note exchange issuances
- BPD Type 2b meeting with FDA planned for second half 2026 to discuss remaining development program requirements
Financial Impact
Q1 2026 net loss of $11.8M vs net income of $9.1M in Q1 2025; operating expenses increased to $5.9M from $0.5M; cash burn rate ~$2M/month with runway into Q3 2026
Risk Factors
- Cash runway only into Q3 2026 — likely needs additional financing before next FDA milestone
- Pre-revenue with no approved products; ABP-450 faces long regulatory path with no guarantee of approval
- Massive share dilution (shares outstanding more than doubled from year-end 2025) depresses per-share value
- Single-product pipeline risk — failure of ABP-450 program would be value-destructive
- NYSE American continued listing standards risk flagged in forward-looking statements
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001837607-26-000041 |
| Document: aeon-20260514x8k.htm | 0001837607-26-000041 |
| Document: 0001837607-26-000041-index-headers.html | 0001837607-26-000041 |
| Document: 0001837607-26-000041-index.html | 0001837607-26-000041 |
| Document: 0001837607-26-000041.txt | 0001837607-26-000041 |
| 8-K Data (Synthetic) | 0001837607-26-000041 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
26d ago
|
8-K
| $0.7220 $0.7770 | ▲ +7.62% | ▲ +6.65% | $0.7300 (+1.11%) |
|
Apr 29, 2026
5w ago
|
DEFA14A
| $0.9230 $0.9100 | ▼ −1.41% | ▼ −3.14% | $0.7300 (−20.91%) |
|
Apr 3, 2026
9w ago
|
8-K
| $0.9100 $0.8590 | ▲ +5.60% | ▲ +9.74% | $0.7300 (+19.78%) |
|
Apr 3, 2026
9w ago
|
Press Release
| $0.9100 $0.8590 | ▲ +5.60% | ▲ +9.74% | $0.7300 (+19.78%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $0.9850 $0.9000 | ▼ −8.63% | ▼ −12.57% | $0.7300 (−25.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access